MacEwen E G, Harvey H J, Patnaik A K, Mooney S, Hayes A, Kurzman I, Hardy W D
J Biol Response Mod. 1985 Aug;4(4):418-26.
Three hundred and forty-five dogs with mammary tumors were initially evaluated for study. One hundred and forty-four dogs with untreated malignant mammary tumors (136 adenocarcinomas, 5 malignant mixed, 3 sarcomas) were selected for study. All dogs were clinically staged and stratified on the basis of tumor volume and body weight. Dogs were randomized to either a radical mastectomy or simple mastectomy group, and then further randomized to a levamisole or placebo group. There was no significant difference in either survival time or cancer-free survival time between the surgery groups or between the levamisole and placebo groups. The most significant prognostic factor was tumor volume; dogs with tumors less than 41 cc had significantly enhanced survival time (p = 0.0007) and cancer-free survival time (p = 0.0005).
最初对345只患有乳腺肿瘤的犬进行了研究评估。选择了144只未经治疗的恶性乳腺肿瘤犬（136只腺癌、5只恶性混合瘤、3只肉瘤）进行研究。所有犬均根据肿瘤体积和体重进行临床分期和分层。犬被随机分为根治性乳房切除术组或单纯乳房切除术组，然后进一步随机分为左旋咪唑组或安慰剂组。手术组之间以及左旋咪唑组和安慰剂组之间的生存时间或无癌生存时间均无显著差异。最显著的预后因素是肿瘤体积；肿瘤体积小于41立方厘米的犬生存时间（p = 0.0007）和无癌生存时间（p = 0.0005）显著延长。
